PBN does not compromise the antitumor effects of agonistic CD40 antibody. B6 mice (n = 5/group) were intravenously administered 10⁷ EL4 lymphoma cells and then treated with either rat IgG/DMSO (▪) or anti-CD40 for 4 days beginning on day 3 after EL4 administration. Mice treated with anti-CD40 were administered either DMSO (•) or PBN (□) on the same 4 days (ie, days 3-6). Actual survival is depicted.